FDA Advisory Committee Gives Thumbs Up for L-glutamine for Sickle Cell Disease
The FDA Advisory Committee voted 10-to-3 in favor of approving Endari (L-glutamine) for sickle cell disease.
In the United States, every year over 2,000 children and teenagers are treated with cisplatin. It’s been well known that it causes hearing loss in a proportion of patients.
The FDA has granted Bayer’s copanlisib a Priority Review designation for its New Drug Application (NDA) to treat relapsed or refractory follicular lymphoma patients
Imara Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation to its lead product candidate, IMR-687.
In the past, getting children to stay still for radiation therapy often required general anesthesia. Not anymore – Letting them watch Spongebob or Cars could be all it takes.
Dr Anthony Herbert talks about palliative care specialists in urban areas provide education to health professionals in non-urban areas about palliative care.
Platelet Disorders Support Association (PDSA) provides information for both clinicians and patients to better manage immune thrombocytopenia (ITP).
James Bussel, MD talks about immune thrombocytopenia (ITP) in children, its treatment and some of the data presented at ASPHO's 20th Annual Meeting in Montreal.
Communication is fundamental for delivering medical care. Not all health professionals are properly trained to converse about pediatric palliative care.
Clinical trial shows that the administration of sodium thiosulfate (STS) in pediatric cancer patients receiving cisplatin reduced developing hearing loss.
$vacMongoViewPlus$ $vAR$